Latest news with #iRhythm
Yahoo
21-05-2025
- Business
- Yahoo
iRhythm Technologies to Participate in Upcoming Investor Conferences
SAN FRANCISCO, May 21, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that its management team is scheduled to present at the following investor conferences. William Blair 45th Annual Growth Stock Conference on Wednesday, June 4, 2025, at 2:00 p.m. Central Time (12:00 p.m. Pacific Time) Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2025, at 2:40 p.m. Eastern Time (11:40 a.m. Pacific Time) Truist Securities MedTech Conference on Tuesday, June 17, 2025, at 1:40 p.m. Eastern Time (10:40 a.m. Pacific Time) Interested parties may access live and archived webcasts of the presentations on the 'Events & Presentations' section of the company's investor website at About iRhythm Technologies, Inc. iRhythm is a leading digital health care company that creates trusted solutions that detect, predict, and prevent disease. Combining wearable biosensors and cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heartbeats into clinically actionable information. Through a relentless focus on patient care, iRhythm's vision is to deliver better data, better insights, and better health for all. For additional information about iRhythm, please visit its corporate website at Investor Contact Stephanie Zhadkevich investors@ Media Contact Kassandra Perryirhythm@
Yahoo
21-05-2025
- Business
- Yahoo
iRhythm Technologies to Participate in Upcoming Investor Conferences
SAN FRANCISCO, May 21, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that its management team is scheduled to present at the following investor conferences. William Blair 45th Annual Growth Stock Conference on Wednesday, June 4, 2025, at 2:00 p.m. Central Time (12:00 p.m. Pacific Time) Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2025, at 2:40 p.m. Eastern Time (11:40 a.m. Pacific Time) Truist Securities MedTech Conference on Tuesday, June 17, 2025, at 1:40 p.m. Eastern Time (10:40 a.m. Pacific Time) Interested parties may access live and archived webcasts of the presentations on the 'Events & Presentations' section of the company's investor website at About iRhythm Technologies, Inc. iRhythm is a leading digital health care company that creates trusted solutions that detect, predict, and prevent disease. Combining wearable biosensors and cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heartbeats into clinically actionable information. Through a relentless focus on patient care, iRhythm's vision is to deliver better data, better insights, and better health for all. For additional information about iRhythm, please visit its corporate website at Investor Contact Stephanie Zhadkevich investors@ Media Contact Kassandra Perryirhythm@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16-05-2025
- Business
- Yahoo
IRTC Q1 Earnings Call: Outperformance Driven by Zio AT and Primary Care Channel Expansion
Medical technology company iRhythm Technologies (NASDAQ:IRTC) reported Q1 CY2025 results topping the market's revenue expectations , with sales up 20.3% year on year to $158.7 million. The company's full-year revenue guidance of $695 million at the midpoint came in 2% above analysts' estimates. Its non-GAAP loss of $0.96 per share was 2.5% below analysts' consensus estimates. Is now the time to buy IRTC? Find out in our full research report (it's free). Revenue: $158.7 million vs analyst estimates of $153.6 million (20.3% year-on-year growth, 3.3% beat) Adjusted EPS: -$0.96 vs analyst expectations of -$0.94 (2.5% miss) Adjusted EBITDA: -$2.64 million vs analyst estimates of -$5.03 million (-1.7% margin, 47.6% beat) The company lifted its revenue guidance for the full year to $695 million at the midpoint from $680 million, a 2.2% increase Operating Margin: -20.5%, up from -28.9% in the same quarter last year Free Cash Flow was -$17.31 million compared to -$61.81 million in the same quarter last year Market Capitalization: $4.5 billion iRhythm's first quarter results were shaped by accelerated adoption of its Zio AT product and increasing penetration in primary care channels. CEO Quentin Blackford pointed to strong demand from both new and existing accounts, as well as record onboarding of healthcare providers, as key contributors to the robust unit volume growth. Management highlighted the growing share of long-term continuous monitoring prescriptions originating from primary care settings, emphasizing early diagnosis benefits and improved clinical outcomes for patients previously unaware of arrhythmias. Looking ahead, the company's updated full-year guidance reflects confidence in continued momentum from both Zio AT and undiagnosed arrhythmia monitoring through innovative channel partners. CFO Daniel Wilson stated, 'Zio AT performance was a primary driver of our guidance raise, while innovative channel partners are contributing but remain an emerging opportunity.' Management acknowledged macroeconomic uncertainty but maintained that operational efficiencies, product mix, and upstream care pathway expansion are expected to drive sustainable growth for the remainder of the year. Management attributed the quarter's performance to expansion in core U.S. markets, increased adoption among primary care providers, and strong uptake of the Zio AT product. The company also referenced momentum in international markets and ongoing operational efficiency initiatives. Zio AT Momentum: The Zio AT mobile cardiac telemetry device saw significant uptake, benefiting from both new and existing account additions. Management believes features like 14-day continuous wear differentiate it versus competitors, driving retention and market share gains within the MCT segment. Primary Care Channel Expansion: Nearly one third of long-term continuous monitoring volumes now originate from primary care physicians, up from the low 20s percent a year and a half ago. Management credits its 'land-and-expand' strategy for enabling earlier detection and diagnosis of cardiac arrhythmias, particularly among patients with comorbidities who might otherwise be undiagnosed. Innovative Channel Partners: Contribution from value-based care partners focused on undiagnosed arrhythmia monitoring increased, though still represents a low single-digit percentage of total volume. Management described this as an early-stage but high-potential growth avenue for expanding the market beyond traditional cardiology. International Progress and Japan Launch: The company launched Zio in Japan, the world's second-largest ambulatory cardiac monitoring market, albeit at reimbursement rates equivalent to existing Holter monitors. iRhythm aims to generate local clinical evidence to secure higher reimbursement in the future. European markets, especially the UK, continued to deliver record volume. Regulatory and Operational Focus: Ongoing remediation and compliance activities with the FDA, including addressing warning letter observations, remain a top corporate priority. Management expects to complete remediation efforts by the end of 2025 and has allocated resources to ensure uninterrupted product supply in light of tariff and supply chain uncertainties. Management's outlook for the year centers on sustaining Zio AT momentum, expanding the primary care channel, and executing on operational efficiency, while navigating macroeconomic and reimbursement risks. Sustained Zio AT Growth: Expectations for continued above-average growth from the Zio AT product underpin revenue guidance, as management anticipates retention of recent share gains and further penetration in existing accounts. Primary Care and Innovative Partnerships: The company plans to deepen its presence in primary care and value-based care channels, aiming to address a broader population of undiagnosed arrhythmia patients and expand the total addressable market. Tariff and Supply Chain Risks: Management highlighted potential headwinds from tariffs on imported components and supply chain disruptions, but indicated mitigation strategies are underway, including building inventory and exploring supply chain adjustments. Pricing actions will be considered as a secondary lever. Allen Gong (JPMorgan): Asked about drivers behind the guidance raise and confidence for the rest of the year. Management cited sustained Zio AT momentum and a robust pipeline from innovative channel partners but emphasized caution in embedding emerging contributions into guidance. Kallum Titchmarsh (Morgan Stanley): Inquired about the stickiness of Zio AT share gains and how this frames expectations for the upcoming Zio MCT launch. CEO Quentin Blackford noted that established relationships in existing accounts and product features were key to customer retention and future cross-selling potential. Macauley Kilbane (William Blair): Sought clarification on the impact of Epic Aura integration for workflow efficiencies and volume growth. Management reported early signs of increased prescribing patterns but stated these benefits are not yet fully factored into guidance. Suraj Kalia (Oppenheimer): Requested more detail on growth across different business segments. CFO Daniel Wilson explained that Zio AT outpaced company average growth, primary care volumes now exceed one third of total, and innovative channel partners contributed a small but growing share. Sam Eiber (BTIG): Asked about strategies to offset tariff impacts, specifically whether price increases were under consideration. Management replied that supply chain adjustments are the primary mitigation strategy, with pricing actions as a secondary option. Looking ahead, the StockStory team will monitor (1) the trajectory of Zio AT adoption and retention in both existing and new accounts, (2) the pace of expansion and volume contribution from primary care and innovative channel partners, and (3) progress on international launches, particularly in Japan and Europe. Execution on FDA remediation milestones and the timeline for filing and approval of the next-generation Zio MCT device will also be closely watched. iRhythm currently trades at a forward EV-to-EBITDA ratio of 78.7×. At this valuation, is it a buy or sell post earnings? The answer lies in our free research report. The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years. Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today. Sign in to access your portfolio
Yahoo
05-05-2025
- Business
- Yahoo
Masimo (MASI) Q1 Earnings Report Preview: What To Look For
Medical tech company Masimo (NASDAQ:MASI) will be reporting earnings tomorrow after market close. Here's what investors should know. Masimo beat analysts' revenue expectations by 1.5% last quarter, reporting revenues of $600.7 million, up 9.4% year on year. It was an exceptional quarter for the company, with a solid beat of analysts' EPS estimates and full-year operating income guidance exceeding analysts' expectations. Is Masimo a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Masimo's revenue to decline 25.4% year on year to $367.9 million, a further deceleration from the 12.8% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.21 per share. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Masimo has missed Wall Street's revenue estimates twice over the last two years. Looking at Masimo's peers in the patient monitoring segment, some have already reported their Q1 results, giving us a hint as to what we can expect. iRhythm delivered year-on-year revenue growth of 20.3%, beating analysts' expectations by 3.3%, and ResMed reported revenues up 7.9%, in line with consensus estimates. iRhythm traded up 20.1% following the results while ResMed was also up 10.1%. Read our full analysis of iRhythm's results here and ResMed's results here. There has been positive sentiment among investors in the patient monitoring segment, with share prices up 4.9% on average over the last month. Masimo is up 10.3% during the same time and is heading into earnings with an average analyst price target of $195.70 (compared to the current share price of $165.87). Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. Sign in to access your portfolio
Yahoo
02-05-2025
- Business
- Yahoo
Apple downgraded, Reddit upgraded: Wall Street's top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The 5 Upgrades: Bernstein upgraded Reddit (RDDT) to Market Perform from Underperform with a price target of $130, up from $110, following the Q1 report. The firm cites the company's "strong execution" for the upgrade. Wells Fargo upgraded iRhythm (IRTC) to Overweight from Equal Weight with a price target of $130, up from $104. The firm says strong trends in iRhythm's underlying business support upside to the company's raised guidance. Oppenheimer upgraded AutoZone (AZO) to Outperform from Perform with a $4,600 price target. AutoZone's "historically discounted relative valuation" makes for "an intriguing buying opportunity," the firm contends. Craig-Hallum upgraded A10 Networks (ATEN) to Buy from Hold with a $20 price target following better Q1 results and reiterated confidence in high-single digits topline growth this year. Evercore ISI upgraded Cullen/Frost (CFR) to In Line from Underperform with a price target of $132, up from $130. Coming out of Q1 results, the firm is increasing its 2025 and 2026 EPS estimates by 5% and 2%, respectively, to reflect a more constructive top line outlook. Top 5 Downgrades: Jefferies downgraded Apple (AAPL) to Underperform from Hold with a price target of $170.62, up from $167.88. The March quarter was in line with expectations and management indicated limited pull in for fiscal Q2, but guided only low-single to mid-single digit revenue growth and estimated a $900M tariff impact in the next quarter, the firm tells investors. Rosenblatt also downgraded Apple to Neutral from Buy with a price target of $217, down from $223, following the fiscal Q2 report. Wells Fargo downgraded Block (XYZ) to Equal Weight from Overweight with a price target of $50, down from $95, following the Q1 report. The combination of "a heavily back half weighted" guidance, growing credit contributions and numerous Cash App monetization "red flags make it too difficult to recommend shares at current levels," the firm tells investors in a research note. BMO Capital, Seaport Research and Benchmark also downgraded Block to Neutral-equivalent ratings. Wedbush downgraded Airbnb (ABNB) to Neutral from Outperform with a price target of $135, down from $150. Airbnb reported "healthy" Q1 results, but the company's Q2 outlook was below expectations, notes the firm, which also says forward guidance was "disappointing relative to expectations" and that management commentary suggests emerging evidence of a slowdown in U.S. travel. Goldman Sachs downgraded Becton Dickinson (BDX) to Neutral from Buy with a price target of $192, down from $256. The company's forward outlook for organic revenue growth has shifted from 5%-6% two years ago to 3%-4% under current operating dynamics, the firm tells investors in a research note. Piper Sandler also downgraded the stock to Neutral. KeyBanc downgraded Cable One (CABO) to Sector Weight from Overweight without a price target. The firm views the company's Q1 results as "extremely disappointing." Raymond James also downgraded the name to Market Perform. Top 5 Initiations: RBC Capital reinstated coverage of Diamondback Energy (FANG) with an Outperform rating and $180 price target. The firm says the shares are likely to trade at a premium to peers given its low-cost structure and deep inventory of tier-1 acreage in the Midland Permian. Citi initiated coverage of Structure Therapeutics (GPCR) with a Buy rating and $60 price target. Citi believes aleniglipron has the potential to be competitive in the obesity market given "encouraging" weight loss data and favorable tolerability. Alliance Global Partners initiated coverage of MediWound (MDWD) with a Buy rating and $25 price target. The firm's Buy rating is based on an expected near-term manufacturing capacity increase to expand NexoBrid sales, while longer-term it believes that the pipeline drug EscharEx could be "a transformative new product that could drive sustained profitability." TD Cowen initiated coverage of Grace Therapeutics (GRCE) with a Buy rating and $12 price target. rating. Based on the Phase III results, TD's consultants believe that GTx-104 will be a welcome alternative treatment for aneurysmal subarachnoid hemorrhage. JPMorgan initiated coverage of CG Oncology (CGON) with an Overweight rating and $41 price target. The firm believes CG's lead asset, Cretostimogene, is well positioned as a "strong player in the evolving" bladder- sparing treatment landscape amid the shortage of Bacillus Calmette-Guerin.
